Autolus Therapeutics Stock Performance
| AUTL Stock | USD 1.40 0.02 1.45% |
On a scale of 0 to 100, Autolus Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 2.23, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Autolus Therapeutics will likely underperform. Please check Autolus Therapeutics' value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Autolus Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Autolus Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, Autolus Therapeutics disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | NICE Recommends AUCATZYL as a Treatment Option for Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia | 11/25/2025 |
2 | How Autolus Therapeutics plc stock valuation compares with sector - 2025 Investor Takeaways Expert Curated Trade Setup Alerts - | 12/19/2025 |
3 | Aug Shorts Can Autolus Therapeutics plc Common Stock 6A3A stock expand revenue streams - July 2025 Fed Impact Free Reliable Trade Execution Plans - moha.gov.vn | 01/05/2026 |
4 | Autolus Therapeutics to Evaluate Automated Manufacturing of AUCATZYL on the Cellares Cell ShuttlePlatform | 01/06/2026 |
5 | Autolus Therapeutics Is Down 25.0 percent After Raising 2026 Revenue Guidance And Advancing Obe-cel Trials | 01/13/2026 |
6 | Autolus Therapeutics A Biotech With A 545 percent Potential Upside - Investor Outlook - DirectorsTalk Interviews | 01/16/2026 |
7 | Autolus Therapeutics Downgraded to Strong Sell Rating by Zacks Research | 01/23/2026 |
8 | The Market Doesnt Like What It Sees From Autolus Therapeutics plcs Revenues Yet As Shares Tumble 26 | 02/03/2026 |
9 | Autolus Therapeutics Plc Stock Analysis A Biotech Gem With 606 percent Potential Upside - DirectorsTalk Interviews | 02/06/2026 |
| Begin Period Cash Flow | 240.3 M | |
| Total Cashflows From Investing Activities | -394.6 M |
Autolus Therapeutics Relative Risk vs. Return Landscape
If you would invest 127.00 in Autolus Therapeutics on November 19, 2025 and sell it today you would earn a total of 13.00 from holding Autolus Therapeutics or generate 10.24% return on investment over 90 days. Autolus Therapeutics is currently generating 0.2802% in daily expected returns and assumes 4.8647% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Autolus, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Autolus Therapeutics Target Price Odds to finish over Current Price
The tendency of Autolus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.40 | 90 days | 1.40 | about 70.88 |
Based on a normal probability distribution, the odds of Autolus Therapeutics to move above the current price in 90 days from now is about 70.88 (This Autolus Therapeutics probability density function shows the probability of Autolus Stock to fall within a particular range of prices over 90 days) .
Autolus Therapeutics Price Density |
| Price |
Predictive Modules for Autolus Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Autolus Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Autolus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Autolus Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Autolus Therapeutics is not an exception. The market had few large corrections towards the Autolus Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Autolus Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Autolus Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.08 | |
β | Beta against Dow Jones | 2.23 | |
σ | Overall volatility | 0.20 | |
Ir | Information ratio | 0.03 |
Autolus Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Autolus Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Autolus Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Autolus Therapeutics may become a speculative penny stock | |
| Autolus Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 10.12 M. Net Loss for the year was (220.66 M) with loss before overhead, payroll, taxes, and interest of (135.38 M). | |
| Autolus Therapeutics currently holds about 216.44 M in cash with (206.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Autolus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Autolus Therapeutics Plc Stock Analysis A Biotech Gem With 606 percent Potential Upside - DirectorsTalk Interviews |
Autolus Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Autolus Stock often depends not only on the future outlook of the current and potential Autolus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Autolus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 255.2 M | |
| Cash And Short Term Investments | 588 M |
Autolus Therapeutics Fundamentals Growth
Autolus Stock prices reflect investors' perceptions of the future prospects and financial health of Autolus Therapeutics, and Autolus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Autolus Stock performance.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.23 | ||||
| Operating Margin | (3.38) % | ||||
| Current Valuation | 73.68 M | ||||
| Shares Outstanding | 266.14 M | ||||
| Price To Earning | (19.33) X | ||||
| Price To Book | 1.41 X | ||||
| Price To Sales | 7.29 X | ||||
| Revenue | 10.12 M | ||||
| Gross Profit | (135.38 M) | ||||
| EBITDA | (233.07 M) | ||||
| Net Income | (220.66 M) | ||||
| Cash And Equivalents | 216.44 M | ||||
| Cash Per Share | 2.38 X | ||||
| Total Debt | 52.63 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 7.29 X | ||||
| Book Value Per Share | 1.00 X | ||||
| Cash Flow From Operations | (206.27 M) | ||||
| Earnings Per Share | (0.83) X | ||||
| Market Capitalization | 372.6 M | ||||
| Total Asset | 782.73 M | ||||
| Retained Earnings | (1.1 B) | ||||
| Working Capital | 600.19 M | ||||
| Current Asset | 102.22 M | ||||
| Current Liabilities | 6.46 M | ||||
About Autolus Therapeutics Performance
By examining Autolus Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Autolus Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Autolus Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 12.32 | 15.07 | |
| Return On Tangible Assets | (0.26) | (0.27) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | (0.59) | (0.62) |
Things to note about Autolus Therapeutics performance evaluation
Checking the ongoing alerts about Autolus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Autolus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Autolus Therapeutics may become a speculative penny stock | |
| Autolus Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 10.12 M. Net Loss for the year was (220.66 M) with loss before overhead, payroll, taxes, and interest of (135.38 M). | |
| Autolus Therapeutics currently holds about 216.44 M in cash with (206.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Autolus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 71.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Autolus Therapeutics Plc Stock Analysis A Biotech Gem With 606 percent Potential Upside - DirectorsTalk Interviews |
- Analyzing Autolus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Autolus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Autolus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Autolus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Autolus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Autolus Therapeutics' stock. These opinions can provide insight into Autolus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Autolus Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth (0.11) | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Autolus Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Autolus Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Autolus Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.